Volume 2.21 | Jun 10

Prostate Cell News 2.21, June 10, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY

Interleukin-1α Mediates the Anti-Proliferative Effects of 1,25 Dihydroxyvitamin D3 in Prostate
Progenitor/Stem Cells

The studies established a system to study the molecular profile of adult prostate progenitor/stem cells differentiation, proliferation, and senescence, and they point to an important new role for interluekin-1α in vitamin D3 signaling in prostate progenitor/stem cells. [Cancer Res]

ProstaCult_645x110_v02

SCIENCE NEWS

Drug Shown to Significantly Improve Survival in Men with Metastatic Prostate Cancer While Exploring A Potential Biomarker to Measure Treatment Response
The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. [Press release from Memorial Sloan-Kettering Cancer Center discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology]

Drug Shows Promise in Prostate Cancer Spread to Bone
A new drug to treat prostate cancer shows early promise, particularly against tumors that have spread to the bone, a multi-site study shows. [Press release from the University of Michigan Health System discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology]

Targeted Therapy Promising for Cancer Patients
Customizing targeted therapies to each tumor’s molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research. [Press release from The University of Texas MD Anderson Cancer Center discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology]

Phase II Study Evaluates Clinical Benefit of REVLIMID® in Combination Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer
Celgene International Sàrl announced results from a Phase II study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer. [Press release from Celgene International Sarl discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology]

Myriad’s PROLARIS® Test Shown to Significantly Predict Prostate Cancer Outcome from Needle Biopsy Tissue
Myriad Genetics, Inc. announced that a presentation entitled “Prognostic Value of a 46-Gene Cell Cycle Progression RNA Signature for Prostate Cancer Death in a Conservatively Managed Watchful Waiting Needle Biopsy Cohort” was presented. [Press release from Myriad Genetics, Inc. discussing research presented at the 2011 Annual Meeting of the American Society of Clinical Oncology]

ON144-FreeTShirt_645x110
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Effect of ON 01910.Na, an Anticancer Mitotic Inhibitor, on Cell Cycle Progression Correlates with RanGAP1 Hyperphosphorylation
Scientists examined ON 01910.Na (benzyl styryl sulfone)’s effect on DNA damage signaling molecules upstream of Cdc25C, (Chk1, Chk2, and H2AX), as well as on RanGAP1·SUMO1, a mitosis coordinator. [Cancer Res]

The Suppression of Prostate LNCaP Cancer Cells Growth by Selenium Nanoparticles through Akt/Mdm2/AR Controlled Apoptosis
Researchers prepared selenium nanoparticles and investigated its inherent anticancer mechanisms. They found that selenium nanoparticles inhibit growth of prostate LNCaP cancer cells partially through caspases mediated apoptosis. [Biomaterials]

Phosphorylation and Interaction of Myopodin by Integrin-Link Kinase Lead to Suppression of Cell Growth and Motility in Prostate Cancer Cells
In this report, investigators showed that the N-terminus of myopodin binds integrin-linked kinase both in vitro and in vivo. [Oncogene]

Image-Guided Prostate Cancer Therapy Using Aptamer-Functionalized Thermally Cross-Linked Superparamagnetic Iron Oxide Nanoparticles
After Dox molecules were loaded onto the Apt–hybr–TCL-SPION through the intercalation of Dox to the CG-rich duplex containing prostate-specific membrane antigen aptamer as well as electrostatic interaction between the Dox-and-polymer coating layer of the nanoparticles, the resulting [email protected]–hybr–TCL-SPION showed selective drug-delivery efficacy in the LNCaP xenograft mouse model. [Small]

2′-5′ Oligoadenylate Synthetase 1 Polymorphism Is Associated with Prostate Cancer
In this study, the authors investigated the association of the functional 2′-5′ oligoadenylate synthetase polymorphism (rs2660) with prostate cancer. [Cancer]

ARFGAP3, an Androgen Target Gene, Promotes Prostate Cancer Cell Proliferation and Migration
In the present study, scientists examined the contribution of ADP ribosylation factor GTPase-activating protein 3 (ARFGAP3) to prostate cancer cell biology. [Int J Cancer]

Diabetes Causes Multiple Genetic Alterations and Downregulates Expression of DNA Repair Genes in the Prostate
In this study, researchers performed a whole-genome cDNA microarray analysis using a streptozotocin-induced diabetic rat model to identify the effects of diabetes on the gene expression profiles in prostate. [Lab Invest]

Endoplasmic Reticulum Stress Drives Lipocalin 2 Upregulation in Prostate Cancer Cells in an NF-Kappa B-Dependent Manner
Investigators hypothesized that the tumor cell unfolded protein response process regulates Lipocalin 2
production. [BMC Cancer]

Troglitazone Suppresses c-Myc Levels in Human Prostate Cancer Cells Via a Peroxisome Proliferator Activated Receptor Gamma-Independent Mechanism
To understand the signaling pathways involved in troglitazone-induced decreases in prostate cancer growth, investigators examined the effect of troglitazone on androgen-independent C4-2 human prostate cancer cells. [Cancer Biol Ther]

Epidermal Growth Factor Increases Leukemia/Lymphoma Related Factor/POK Erythroid Myeloid Ontogenic Factor (LRF/Pokemon) Expression in Human Prostate Cancer Cells
The aim of this study was to examine the regulation of LRF expression in human prostate cells. [Exp Mol Pathol]

CLINICAL RESEARCH

The CAPRA-S Score: A Straightforward Tool for Improved Prediction of Outcomes After Radical Prostatectomy
The Cancer of the Prostate Risk Assessment Score (CAPRA-S) offers good discriminatory accuracy, calibration, and ease of calculation for clinical and research settings. [Cancer]

Preoperative Serum Levels of Early Prostate Cancer Antigen (EPCA) Predict Prostate Cancer Progression in Patients Undergoing Radical Prostatectomy
The goals of this study were to measure preoperative serum EPCA levels in a cohort of prostate cancer patients who were treated with radical prostatectomy, and to investigate whether serum EPCA levels would independently predict cancer prognosis after the surgery. [Prostate]

INDUSTRY NEWS

Purdue Takes Prostate Cancer Treatment from Concept to Clinical Trial
A clinical trial for a new technology to diagnose and treat prostate cancer marks the first time Purdue University has directed the entire pathway of a therapeutic product from early research to patient treatment. [Purdue University Press Release]

Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Bayer Healthcare announced that the Phase III ALSYMPCA trial evaluating Bayer’s investigational compound Alpharadin (radium-223 chloride) in patients with castration-resistant prostate cancer and symptomatic bone metastases met its primary endpoint by significantly improving overall survival. [Bayer Healthcare Press Release]

Exelixis’ Cabozantinib Phase II Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
Exelixis, Inc. reported updated interim data from the fully enrolled cohort of patients with metastatic castration-resistant prostate cancer treated with cabozantinib (XL184) in a phase II adaptive randomized discontinuation trial. [Exelixis, Inc. Press Release]

BioSante Pharmaceuticals Announces Lifting of Clinical Hold on GVAX Prostate Cancer Vaccine
BioSante Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA)’s clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA. [BioSante Pharmaecuticals, Inc. Press Release]

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS

NEW American Association for Cancer Research: Metabolism and Cancer
October 16-19, 2011
Baltimore, United States

Visit our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

Chemist (STEMCELL Technologies)

Research and Development Senior Technologist (STEMCELL Technologies)

Post-doctoral Position – Molecular Biology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Assistant/Associate Research Scientist (New York University)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

forwardafriendicon

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us